GSK Phase III vaccine data 'very encouraging' for reducing meningococcal disease

UK pharma major GSK (LSE: GSK) has announced positive headline results from a Phase III trial of its MenABCWY combination vaccine candidate.

The MenABCWY vaccine candidate, which combines the antigenic components of GSK’s licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY), was administered as two doses given six months apart in healthy individuals aged 10 to 25 years.

All primary endpoints were met, including the non-inferiority of the vaccine candidate for all five Neisseria meningitides serogroups, compared to the licensed meningococcal vaccines Bexsero and Menveo, in terms of an immune response.